Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Part D Rebates: Talking Points Continue, But Deficit Deal Elusive

This article was originally published in RPM Report

Executive Summary

Once again the President is calling for rebates on prescription drugs sold under Medicare Part D. But without a big deficit deal involving entitlement reform, is there any way to enact them?


Related Content

Part D Rebates And Some New Health Policy Proposals Get Deficit Reduction Estimates In CBO Report
Obama Pitches Part D Rx Price Concessions In State Of The Union Address
Merck CEO Frazier Stands Alone As Pharma Signatory Urging Fiscal Cliff Budget Deal
Part D Rebates and the Numbers Game: Pharma Readies for Post-Election Deficit Fight





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts